C4X Discovery Holdings PLC Board Changes (7565P)

TIDMC4XD

RNS Number : 7565P

C4X Discovery Holdings PLC

22 November 2016

This announcement contains inside information

C4X Discovery Holdings plc

("C4XD" or the "Company")

Board Changes

C4XD Strengthens Board with Two Senior Appointments

22 November, 2016 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that Brad Hoy, Chief Financial Officer (CFO), and Dr Craig Fox, Chief Scientific Officer (CSO), will join the Board of Directors with immediate effect. In addition, Brad Hoy has been appointed permanent CFO today following a period as interim CFO.

Brad (aged 53) has more than 20 years' experience in the pharmaceutical and biotechnology industries and has held a number of senior financial and general management positions in both the UK and US. Previously, Brad was Chief Financial Officer of Plethora Solutions Holdings plc, an AIM-listed specialty pharmaceutical company, Chief Executive Officer of Xcellsyz Limited, a UK venture capital-backed life science company, and Senior Director of Geron Corporation's stem-cell focused UK subsidiary. Brad is a co-founder of Seven Hills Venture Partners, a life sciences advisory firm, and currently serves on the Board of Directors for e-Therapeutics plc.

Craig (aged 41) joined C4X Discovery in September 2015 and is an experienced drug-discovery biologist, having worked on and managed a number of discovery and development projects during the past 18 years from initial target selection through to clinical studies. Prior to joining C4X Discovery, Craig was director of Respiratory Research at Pulmagen Therapeutics, a clinical stage company spun out of Argenta in 2010. At Pulmagen, Craig managed several of its collaborations and partnerships, including those with AstraZeneca, Chiesi, Domantis, Dr Reddy's, Skyepharma and Teijin Pharma. Craig was part of the Etiologics Team that merged with Argenta Discovery in 2004 and, prior to that, he worked for Bayer as a Research Scientist.

Commenting on the Board appointments, Dr Clive Dix, CEO of C4X Discovery, said: "We are delighted to have these two highly experienced professionals join our Board. The wealth of knowledge and experience they bring to the Company and its Board will make a significant contribution to executing our strategic plan of becoming the world's most productive drug discovery engine."

Sam Williams, Interim Chairman of the Board of Directors of C4X Discovery, said: "C4X Discovery is building a world-leading discovery engine with cutting edge technologies in target identification and compound design, and a first-class team of scientists and corporate leaders. Brad and Craig are a key part of that effort and I'm delighted that they will both now contribute to the strategy of the Company at Board level."

The information on Brad required to be disclosed under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies is as follows:

Bradley Richard Hoy, aged 53, is currently a director of the following companies:

   --     Castle Three Motor Company Limited 
   --     Evince Technology Limited 
   --     e-Therapeutics PLC 
   --     Hadrian Capital Consulting Limited 
   --     Seven Hills Venture Partners Limited 

In addition, Brad has held the following directorships in the past five years:

   --     Burdica Biomed Limited(1) 
   --     Cytaeon Limited 
   --     Deep Tek Offshore Limited 
   --     Hadrian Capital Limited 

Notes

1. On 1 May 2008, Brad Hoy was appointed as a director of Burdica Biomed Limited. On 5 February 2014 Burdica Biomed was put into administration, which concluded on 29 July 2016. Brad Hoy has not been the subject of public criticism in connection with the administration.

There is no further information on Brad Hoy required to be disclosed under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies.

The information on Craig required to be disclosed under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies is as follows:

Dr Justian Craig Fox, aged 41, is currently a director of the following companies:

   --     C4X Discovery Limited 
   --     Adorial Limited 
   --     Adorial Pharma Limited 
   --     Adorial Technologies Limited 

In addition, Craig has held the following partnerships in the past five years:

   --     Pulmagen Therapeutics LLP 

There is no further information on Craig Fox required to be disclosed under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies.

--ENDS-

For further information, please contact:

C4X Discovery Holdings plc

Clive Dix, Chief Executive Officer 07801 865 803

Zeus Capital Limited

Dan Bate

0161 831 1512

Dominic Wilson/Phil Walker

0203 829 5000

Consilium Strategic Communications

Mary-Jane Elliott, Matthew Neal, Melissa Gardiner 0203 709 5700

About C4X Discovery

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3(R)) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4X's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.

C4X Discovery is advancing its in-house pipeline in addiction, diabetes and inflammation with a number of new drug candidates identified and further progress made towards the clinic. In selecting new targets C4X Discovery will focus on the high-value disease areas of inflammation and neurodegeneration, and will continue to maximise value from opportunistic areas, for example, immuno-oncology.

The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4X to reach multiple value inflexion points since IPO. For additional information please go to: www.c4xdiscovery.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOABRBDBGXDBGLB

(END) Dow Jones Newswires

November 22, 2016 02:02 ET (07:02 GMT)